Shares of Regeneron Pharmaceuticals Inc. shed 7.47% to $558.52 Tuesday, on what proved to be an all-around grim trading ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

Shares of Gilead Sciences Inc. GILD rallied 2.24% to $106.54 Wednesday, on what proved to be an all-around favorable trading ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences Down Nearly 5%, On Track for Largest Percent Decrease Since January 2024 — Data Talk Gilead Sciences, Inc. (GILD) is currently at $97.68, down $5.14 or 4.99% --Would be lowest close ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

The subdued stock price reaction suggests that Gilead Sciences, Inc.'s (NASDAQ:GILD) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors ...

A New York doctor who treated HIV and AIDS patients sued Gilead for violating the False Claims Act with payments to doctors ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.